Trial Profile
Efficacy of Glucagon-like-peptide-1 Agonists and Restrictive vs. Liberal FiO2 in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement - a 2-by-2 Factorial Designed, Randomized Clinical Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Ischaemic heart disorders
- Focus Adverse reactions
- Acronyms GLORIOUS
- 15 Nov 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.
- 24 Oct 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 24 Oct 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.